Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease

Overview

Journal Chronic Obstr Pulm Dis

Date 2021 Feb 20

PMID 33610139

Citations 1

Authors

Samuel L Krachman

Maria Elena Vega

Daohai Yu

Joseph Demidovich

Harsh Patel

Frederic Jaffe

Xavier Soler

Tahseen Shariff

Gilbert E DAlonzo

Wissam Chatila

Sheila Weaver

Yasmin Daraz

Sydney Cohen

Gerard J Criner

Affiliations

Soon will be listed here.

Abstract

Background: Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease (COPD) includes the effects of medications. This study evaluates the effect of the inhaled triple therapy of budesonide-formoterol-tiotropium versus placebo-tiotropium on sleep quality in COPD patients.

Methods: Twenty-three patients (11 [48%] males; age 55 [51-60, 48--5] years; body mass index [BMI] 25 [22-30, 18-40] kg/m; forced expiratory volume in 1 second [FEV]1.10 [0.80 -1.90, 0.60-2.80] L, 42 [31-62, 24-75] % predicted) were studied. Ten patients were randomized to budesonide-formoterol-tiotropium and 13 patients to placebo-tiotropium. At baseline and after 28 days, patients completed spirometry, polysomnography, an Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), COPD-specific St George's Respiratory Questionnaire (SGRQ-C) and short form 36 (SF 36).

Results: After 28 days, there was a significant 29% increase in the bedtime FEV in the budesonide-formoterol-tiotropium group (from 0.75 [0.55-1.30, 0.50-2.40] L to 1.00 [0.75-1.55, 0.50-3.00] L, =0.031), with no change in the placebo-tiotropium group (from 1.20 [0.80-1.50, 0.60-1.90] L to 1.15 [0.75-1.55, 0.50-1.80] L, =0.91). No significant change was found post treatment in sleep efficiency or total sleep time in both the budesonide-formoterol-tiotropium group (from 78 [72-92, 62-98]% to 88 [77-92, 40-98]%, =0.70 and 290 [268-358, 252-382] min to 342 [303-358, 157-372] min, =0.77, respectively) and the placebo-tiotropium group (from 82 [75-88, 46-93]% to 84 [77-87, 62-94]%, =0.96 and 320 [292-350, 180-378] min to 339 [303-349, 241-366] min, =0.79, respectively). While there was no significant change in the arousal index in the budesonide-formoterol-tiotropium group (9 [5-16, 0-48] arousals/hour to 14 [9-17, 2-36] arousals/hour, =0.43), a significant increase was seen in the placebo-tiotropium group (11 [4-13, 3--2] arousals/hour to 17 [11-21, 2-33] arousals/hour, =0.027). Similarly, there was no change in the ESS in the budesonide-formoterol-tiotropium group (6 [3-8, 0-11] to 6 [5-8, 0-1]), =0.44), but a marginally significant increase in the placebo-tiotropium group (8 [5-12, 2-18] to 10 [7-13, 5-18], =0.07), with a significant difference in the ESS 28 days post treatment between the 2 groups (6 [5-8, 0-11] versus 10 [7-13, 5-18], =0.043). There was no significant change in nocturnal oxygenation, sleep architecture, PSQI, SGRQ-C, or SF 36 in both groups.

Conclusion: In patients with COPD, inhaled triple therapy with budesonide-formoterol-tiotropium as compared to placebo-tiotropium improves pulmonary function while preserving sleep quality and architecture.

Citing Articles

Overlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?.

Voulgaris A, Kalkanis A, Steiropoulos P Pulm Ther. 2025; 11(1):1-5.

PMID: 39743657 PMC: 11861818. DOI: 10.1007/s41030-024-00282-y.

References

Short P, Williamson P, Elder D, Lipworth S, Schembri S, Lipworth B . The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2011; 141(1):81-86. DOI: 10.1378/chest.11-0038. View

Dodge R, Cline M, Quan S . The natural history of insomnia and its relationship to respiratory symptoms. Arch Intern Med. 1995; 155(16):1797-800. View

Omachi T, Blanc P, Claman D, Chen H, Yelin E, Julian L . Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012; 13(5):476-83. PMC: 3336048. DOI: 10.1016/j.sleep.2011.12.007. View

Nunes D, Mota R, de Pontes Neto O, Pereira E, de Bruin V, de Bruin P . Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009; 187(3):159-63. DOI: 10.1007/s00408-009-9147-5. View

Frith P, Thompson P, Ratnavadivel R, Chang C, Bremner P, Day P . Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015; 70(6):519-27. PMC: 4453631. DOI: 10.1136/thoraxjnl-2014-206670. View

Kwon J, Wolfe L, Lu B, Kalhan R . Hyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apnea. COPD. 2009; 6(6):441-5. DOI: 10.3109/15412550903433000. View

Budhiraja R, Roth T, Hudgel D, Budhiraja P, Drake C . Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep. 2011; 34(7):859-67. PMC: 3119827. DOI: 10.5665/SLEEP.1114. View

Fleetham J, West P, Mezon B, Conway W, Roth T, Kryger M . Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis. 1982; 126(3):429-33. DOI: 10.1164/arrd.1982.126.3.429. View

Vestbo J, Soriano J, Anderson J, Calverley P, Pauwels R, Jones P . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med. 2004; 98(11):1045-50. DOI: 10.1016/j.rmed.2004.03.017. View

10.

Krachman S, Chatila W, Martin U, Permut I, DAlonzo G, Gaughan J . Physiologic correlates of sleep quality in severe emphysema. COPD. 2011; 8(3):182-8. DOI: 10.3109/15412555.2011.560583. View

11.

Klink M, Dodge R, Quan S . The relation of sleep complaints to respiratory symptoms in a general population. Chest. 1994; 105(1):151-4. DOI: 10.1378/chest.105.1.151. View

12.

Bellia V, Catalano F, Scichilone N, Antonelli Incalzi R, Spatafora M, Vergani C . Sleep disorders in the elderly with and without chronic airflow obstruction: the SARA study. Sleep. 2003; 26(3):318-23. DOI: 10.1093/sleep/26.3.318. View

13.

McNicholas W, Calverley P, Lee A, Edwards J . Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J. 2004; 23(6):825-31. DOI: 10.1183/09031936.04.00085804. View

14.

Fletcher E, Miller J, Divine G, Fletcher J, Miller T . Nocturnal oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions above 60 mm Hg. Chest. 1987; 92(4):604-8. DOI: 10.1378/chest.92.4.604. View

15.

Krachman S, Quaranta A, Berger T, Criner G . Effects of noninvasive positive pressure ventilation on gas exchange and sleep in COPD patients. Chest. 1997; 112(3):623-8. DOI: 10.1378/chest.112.3.623. View

16.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G . Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391(10125):1076-1084. DOI: 10.1016/S0140-6736(18)30206-X. View

17.

Martin R, Bartelson B, Smith P, Hudgel D, Lewis D, Pohl G . Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest. 1999; 115(5):1338-45. DOI: 10.1378/chest.115.5.1338. View

18.

Krachman S, Chatila W, Martin U, Nugent T, Crocetti J, Gaughan J . Effects of lung volume reduction surgery on sleep quality and nocturnal gas exchange in patients with severe emphysema. Chest. 2005; 128(5):3221-8. DOI: 10.1378/chest.128.5.3221. View

19.

Eliasson A, Kashani M, Howard R, Vernalis M, Modlin R . Fatigued on Venus, sleepy on Mars-gender and racial differences in symptoms of sleep apnea. Sleep Breath. 2014; 19(1):99-107. DOI: 10.1007/s11325-014-0968-y. View

20.

Buysse D, Reynolds 3rd C, Monk T, BERMAN S, Kupfer D . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. View